Mutual of America Capital Management LLC Has $11.64 Million Stake in IDEXX Laboratories, Inc. $IDXX

Mutual of America Capital Management LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 18,220 shares of the company’s stock after selling 1,422 shares during the quarter. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $11,641,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blalock Williams LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth $590,000. Arkadios Wealth Advisors acquired a new position in IDEXX Laboratories in the second quarter valued at about $405,000. Orion Porfolio Solutions LLC boosted its holdings in IDEXX Laboratories by 116.6% during the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after buying an additional 5,770 shares during the last quarter. USA Financial Formulas acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $2,381,000. Finally, Beacon Investment Advisory Services Inc. increased its stake in shares of IDEXX Laboratories by 15.7% in the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock valued at $35,932,000 after acquiring an additional 7,616 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. Barclays started coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective on the stock. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Morgan Stanley lifted their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $697.82 on Tuesday. The company has a fifty day moving average price of $706.41 and a 200 day moving average price of $657.44. The firm has a market cap of $55.72 billion, a PE ratio of 55.34, a PEG ratio of 3.71 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.